Sign in

CIK 0001533040 · Non-accelerated filer<br>Smaller reporting company

Phio Pharmaceuticals Corp.

Sign in to watch
Ticker
PHIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
453215903
Phone
(508) 767-3861
Business address
411 SWEDELAND ROAD, SUITE 23-1080, KING OF PRUSSIA, PA, 19406
Former names
RXi Pharmaceuticals Corp
  1. 4 Grant or award President & CEO acquired 80,000 shares (grant or award)
  2. 4 Grant or award Director acquired 37,500 shares (grant or award)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market buy President & CEO bought 5,000 shares at $0.72 ($3,596)
  11. 4 Open-market buy President & CEO bought 4,000 shares at $1.17 ($4,680)
  12. 4 Open-market buy President & CEO bought 2,000 shares at an average $1.24 ($2,487)
  13. 4 Open-market buy Director bought 5,000 shares at an average $1.20 ($5,981)
  14. 4 Open-market buy President & CEO bought 10,000 shares at $1.03 ($10,300)
  15. 4 Open-market buy President & CEO bought 2,500 shares at an average $1.59 ($3,968)
  16. 4 Open-market buy President & CEO bought 3,000 shares at $1.68 ($5,040)
  17. 4 Open-market buy President & CEO bought 4,500 shares at $2.20 ($9,900)
  18. 4 Open-market buy President & CEO bought 5,000 shares at $2.08 ($10,390)
  19. 4 Open-market buy President & CEO bought 10,000 shares at an average $2.18 ($21,849)
  20. 4 Open-market buy No longer 10% owner bought 400 shares at $2.48 ($992)

Page 10 of 15 · 281 filings